Human Leukocyte Antigen Testing Market to grow at a CAGR of 7.5% from 2022 to 2028Posted by mahesh on October 4th, 2022 According to our latest research study on “Human Leukocyte Antigen (HLA) Testing Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by product and service, technology, and end user,” the human leukocyte antigen (HLA) testing market size is projected to reach US$ 1,155.65 million by 2028 from US$ 697.74 million in 2021; it is estimated to grow at a CAGR of 7.5% from 2022 to 2028. The report highlights trends prevailing in the market and factors governing the growth of the market. Human leukocyte antigens play an essential part in the body's immune response to external substances. The principal use for human leukocyte antigen (HLA) testing is to match organ and tissue transplant recipients with compatible donors. HLA testing also involves screening transplant recipients for the presence of antibodies that might target the donated tissue or organ as part of an immune response. The growth of the market is attributed to increasing plasma donation and organ transplants procedures and increasing applications of HLA testing drive the market growth. However, increasing accuracy errors hampers the market growth. Several in organic approaches, such as product launches, and expansion in the human leukocyte antigen (HLA) testing, have resulted in the growth of the market. Likewise, inorganic strategies such as mergers & acquisitions, and collaboration have helped the company to strengthen its revenue, which allows the company to hold a strong position in the market. Request Sample PDF Brochure of Human Leukocyte Antigen Testing Market @ https://www.theinsightpartners.com/sample/TIPRE00021578/ Increasing Government Funding for Organ Donation Creates Opportunities for Human Leukocyte Antigen (HLA) Testing Market Players Living organ donations and deceased organ donations (DCD) are the two types of organ donations. The demand for both types of organ donations is rising day by day due to the elevating cases of chronic illnesses. According to the US Human Resource and Service Administration (HRSA), ~21 people die waiting for an organ in the US every day. More than 107,380 men, women, and children in the country await life-saving organ transplants. Additionally, as per the Ministry of Health and Family Welfare (MoHFW) of the Government of India, annually 500,000 people die because of non-availability of organs, 200,000 people die due to liver disorders, and 50,000 people die because of heart disease. Moreover, 150,000 people await a kidney transplant, but only 5,000 get kidneys for transplantation. These numbers indicate the need for organ donors, which is much greater than the actual number of donations. Similar scenarios have been found in other nations of the world. Product and Services-Based Insights The human leukocyte antigen (HLA) testing market, based on product and service type, has been segmented into reagents and consumables, instruments, and software and services. The reagent and consumables segment held the largest share of the market in 2021. However, the instrument segment is expected to register the highest CAGR in the human leukocyte antigen (HLA) testing market during 2022–2028. Key Players - Market leaders operating in the market have undertaken various organic and inorganic growth strategies. The human leukocyte antigen (HLA) testing market majorly consists of players like Astrazeneca, Pfizer, Inc., Baxter International, Inc., Biocon, Fresenius SE & Co. KGaA, GlaxoSmithKline Plc, Hikma Pharmaceuticals, Johnson & Johnson Services, Inc., Lupin, Ltd., Merck & Co., Inc., and Mylan N.V. Fresenius SE & Co. KGaA & Pfizer, Inc., and Thermo Fisher Scientific, Inc., and Luminex Corporation are the topmost two companies in the market. Jan-2020 Thermo Fisher Scientific plans to acquire point-of-care molecular diagnostics firm Mesa Biotech for up to 0 million, the company said on Tuesday. Under the terms of a definitive agreement, Thermo Fisher will pay approximately 0 million in cash and up to an additional 0 million in cash if certain milestones are met after the acquisition. Aug-2021 BioReference Laboratories announced that it has acquired the Ariosa centralized prenatal testing business from Roche. Ariosa’s non-invasive prenatal screening (NIPS) test, the Harmony Prenatal Test, has been performed in over 1.5 million patients. GenPath, BioReference’s specialty health division, currently offers ClariTest Core, which utilizes the same core technology as the Harmony Prenatal Test, so the acquisition of Ariosa will complement this current NIPS offering, BioReference Laboratories said. Feb-2022 Takara Bio has announced that they will be opening an expansion of its manufacturing facility, the center for Gene and Cell Processing (CGCP), at the company's headquarters in Shiga, Japan. The expansion of the facility, which went into operation in 2020, features increased production capacity. These new equipment include 200 L bioreactors, 2,000 L fermenters, and large flow centrifuge and purification systems. Jan-2021 Omixon announce that their flagship Holotype HLA assay and software solution as well as Monotype HLA configuration for disease association studies for HLA typing by Next Generation Sequencing (NGS) has been selected as the HLA typing solution of choice by the Establishment Francais du Sang ( the French National Blood Service, EFS). The company has been the supplier of NGS-based HLA typing reagents to EFS for the last four years with local support provided by Wiretech, and this announcement marks the start of a new four-year term worth >US 12.51 million over the life of the contract. Access Full Report @ https://www.theinsightpartners.com/reports/human-leukocyte-antigen-hla-testing-market About Us: The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Life Science, Technology, Healthcare, Manufacturing, Automotive and Defense, Food Beverages, Chemical etc. Contact Us : Contact Person: Sameer Joshi E-mail: sales@theinsightpartners.com Phone: +1-646-491-9876 Like it? Share it! More by this author |